Adaptor proteins link surface receptors to intracellular signaling pathways and potentially control the way cells respond to nutrient availability. Mice deficient in p66Shc, the most recently evolved isoform of the Shc1 adaptor proteins and a mediator of receptor tyrosine kinase signaling, display resistance to diabetes and obesity. Using quantitative mass spectrometry, we found that p66Shc inhibited glucose metabolism. Depletion of p66Shc enhanced glycolysis and increased the allocation of glucose-derived carbon into anabolic metabolism, characteristics of a metabolic shift called the Warburg effect. This change in metabolism was mediated by the mammalian target of rapamycin (mTOR) because inhibition of mTOR with rapamycin reversed the glycolytic phenotype caused by p66Shc deficiency. Thus, unlike the other isoforms of Shc1, p66Shc appears to antagonize insulin and mTOR signaling, which limits glucose uptake and metabolism. Our results identify a critical inhibitory role for p66Shc in anabolic metabolism.
INTRODUCTION
A common mechanism through which activated receptor tyrosine kinases (RTKs) control intracellular pathways involves recruitment of Src homology 2 (SH2)-containing proteins with regulatory or adaptor functions (1) . For example, the Grb10 adaptor is an inhibitor of insulin signaling that is stabilized by mammalian target of rapamycin (mTOR)-mediated phosphorylation and suppresses insulin sensitivity in vivo (2) (3) (4) (5) . Loss of inhibitors can result in dysregulation of growth factor signaling, promoting the rewiring of metabolic pathways in a manner that supports rapid growth and cell survival. A major change that occurs in such proliferating cells is enhanced glucose uptake and catabolism, accompanied by increased lactate production, a phenomenon referred to as the "Warburg effect" (6, 7) . This rewiring provides proliferating cells with biosynthetic precursors from increased glucosederived carbon intermediates that are essential for increasing cell biomass.
The gene for the Shc1 adaptor protein encodes three isoforms in mammals: p46, p52, and p66. These proteins share a modular arrangement of a phosphotyrosine binding (PTB) domain, a collagen homology 1 (CH1) region, and an SH2 domain (Fig. 1A ). p66Shc and p52Shc or p46Shc (p52/p46Shc) are encoded by two transcripts that differ in the use of alternative 5′ coding exons, whereas p46Shc and p52Shc originate from different translation start sites in the same mRNA, such that p46Shc is an N-terminally truncated form of p52Shc (8) . p52/p46Shc isoforms are scaffolds that associate with activated RTKs and amplify signaling to the Ras-ERK (extracellular signalregulated kinase) mitogen-activated protein kinase and phosphatidylinositol 3′-kinase (PI3K)-Akt pathways. The p66Shc isoform emerged with vertebrates and is characterized by an N-terminal collagen homology 2 (CH2) extension (9) . p66Shc has been reported to promote oxidative stress and proapoptotic signaling in HeLa cells and murine embryonic fibroblasts (MEFs) (9) (10) (11) . Unlike p52/p46, the abundance of p66Shc is substantially decreased in ErbB2-overexpressing breast cancer cell lines, suggesting that p66Shc may function as an antagonist of p52/p46Shc, possibly acting as a tumor suppressor (12) . Inactivation of p66Shc in mice improves glucose tolerance and insulin sensitivity (13, 14) and confers resistance to hyperglycemiainduced endothelial dysfunction (15) . However, under nutrient stress conditions, mice lacking p66Shc are short-lived (16) . These studies suggest that p66Shc may suppress metabolism by dampening growth factor signaling.
Using targeted mass spectrometry (MS)-based metabolomics, we have analyzed the effects of p66Shc on metabolic pathways. Our data suggest that silencing of p66Shc improves glucose uptake and redirects glucose carbon toward anabolic metabolism and increased cell size. In addition, we show that the effects of p66Shc are mediated, in part, by mTOR complexes 1 and 2 (mTORC1 and mTORC2, respectively). Our work reveals a role for p66Shc as an inhibitor of growth factor signaling and cell metabolism.
RESULTS

Loss of p66Shc enhances glycolytic metabolism
To elucidate the involvement of p66Shc in cellular metabolism, we performed a targeted metabolomic analysis using liquid chromatography-tandem MS (LC-MS/MS) in multiple reaction monitoring (MRM) mode. We measured~250 metabolites in positive-or negative-mode runs (table S1) and validated metabolite spectral patterns using standards. To assess the role of p66Shc in cancer cell metabolism, we initially used HeLa cells that were stably transfected with either a short hairpin RNA (shRNA) that specifically targets the isoform p66Shc or a control hairpin (Fig. 1B) (17) . When we analyzed the profiles of metabolites extracted from the two cell types, we noted that loss of p66Shc resulted in increased abundance of intermediates of glucose metabolism (Fig. 1C and fig. S1 ). Specifically, p66Shc deficiency was accompanied by significant increases in glucose-6-phosphate (G6P) and downstream glycolytic intermediates including fructose-6-phosphate (F6P), fructose-1,6-bisphosphate (F1,6BP), phosphoenolpyruvate (PEP), and pyruvate (Fig. 1D ). p66Shc-deficient HeLa cells produced more lactate than did control cells, consistent with the Warburg effect. The metabolic shift also redirects glucose-derived citrate from the tricarboxylic acid cycle into lipid synthesis to generate biomass (18) . Consistent with this effect, p66Shc-deficient cells had higher citrate concentrations (Fig. 1D ). These data suggest that depletion of p66Shc is sufficient to enhance anabolic metabolism in HeLa cells.
Loss of p66Shc promotes glucose metabolism through the pentose phosphate and hexosamine biosynthesis pathways
In addition to their role in glycolysis, G6P and F6P are precursors of the hexosamine biosynthesis and pentose phosphate pathways, which are essential anabolic pathways in proliferating cells. The hexosamine biosynthesis pathway provides uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) as a substrate for O-GlcNAcylation of cytosolic proteins and N-and O-glycosylation of proteins produced in the secretory pathway. The pentose phosphate pathway provides ribose for nucleic acid synthesis and NADPH [reduced form of nicotinamide adenine dinucleotide phosphate (NADP + )] to maintain the reductive environment of the cell. In HeLa cells lacking p66Shc, we observed increases in the abundance of N-acetylglucosamine-6-phosphate (GlcNAcP) and UDP-GlcNAc (nearly four-and twofold, respectively), the major products of the hexosamine biosynthesis pathway (Fig. 1E) . A two-to threefold increase in UDP-GlcNAc enhances N-glycosylation of growth factor receptors, thereby promoting positive feedback to signaling (19, 20) . The concentrations of ribose-5-phosphate (R5P) and xylulose-5-phosphate (X5P) were also increased, which may involve the oxidative pentose phosphate pathway, which contributes to redox balance (Fig. 1F) .
Restoring p66Shc expression in p66Shc-deficient MEFs inhibits glycolytic metabolism
To test whether p66Shc was necessary for enhanced glycolytic metabolism, we stably infected immortalized p66Shc knockout (KO) MEFs with either green fluorescent protein (GFP) or 3xFLAG-p66Shc retroviral vectors (hereinafter referred to as KO and p66 + MEFs, respectively) ( Fig. 2A) . Principal components analysis was used to evaluate replicate consistency, and revealed a notable difference in the overall metabolic profiles of the p66Shc KO and p66 + cells ( fig. S2 ). Consistent with the p66Shc-mediated effects in HeLa cells, F6P and G6P were among the metabolites with the most significant changes, and the abundance of glycolytic intermediates was generally lower in p66 + MEFs compared to the KO cells ( Table 1 ). The abundance of glycolytic intermediates changed to a similar extent in MEFs as in HeLa cells; we observed a nearly threefold decrease in G6P concentrations and a concomitant decrease in downstream three-carbon glycolytic metabolites including PEP and lactate in p66 + cells (Fig. 2B ). The lower concentration of citrate in p66 + cells was accompanied by a concomitant decrease in the amounts of the fatty acid synthesis precursors acetyl-coenzyme A (CoA) and malonyl-CoA (Fig. 2C) . Malonyl-CoA is a high-energy and committed intermediate in fatty acid biosynthesis and is thus exclusively an anabolic metabolite. These results suggest that p66Shc inhibits de novo lipid biosynthesis. In addition, the abundance of intermediates in the hexosamine biosynthesis and pentose phosphate pathways was decreased in p66 + MEFs (Fig. 2, D and E). This profile confirms that p66Shc deficiency in nontransformed cells enhanced glycolytic flux at the expense of decreasing oxidative mitochondrial metabolism. Indeed, p66Shc-deficient MEFs displayed lower oxygen consumption (Fig. 2F ) but improved energy utilization [adenosine 5′-monophosphate (AMP)/adenosine 5′-triphosphate (ATP)] (Fig. 2G ).
p66Shc expression inhibits amino acid biosynthesis and pyrimidine metabolism
The difference in glucose uptake between p66Shc-deficient and p66Shc-competent MEFs was~33% at most. However, the difference in the abundance of glycolytic metabolites ranged between 1.5-and 3-fold. These results suggested a contribution from other nutrients such as amino acids that reversibly exchange with glycolytic intermediates. We detected higher amounts of nonessential amino acids, including alanine, serine, and aspartate, in p66Shc-deficient MEFs (Fig. 3A) . To determine whether the effect of p66Shc signaling on the steady-state abundance of nonessential amino acids reflects regulation of metabolic flux through de novo synthesis, we measured the relative flux with a pulse of stable isotope-labeled 15 N-glutamine. Increased incorporation of labeled nitrogen into nonessential amino acids was detected in p66Shc KO MEFs (Fig. 3B) . Increased flux of nitrogen from extracellular glutamine into nonessential amino acids is consistent with the reprogramming that favors anabolism.
Pyrimidine derivatives [dCTP (2′-deoxycytidine 5′-triphosphate) and UTP (uridine 5′-triphosphate)] were among the top 10 metabolites whose abundance was significantly decreased in p66 + MEFs (Table 1 ). Pyrimidine sent SD of at least three biological replicates (*P < 0.05, **P < 0.01, ***P < 0.001). nucleotides are required as high-energy donors for phospholipid and glycoconjugate biosynthesis. p66 + MEFs showed lower amounts of the pyrimidine synthesis intermediates orotate and dihydroorotate as compared to KO MEFs (Fig. 3C ). These results confirm that p66Shc inhibits anabolic metabolic pathways, and demonstrate a prominent role for p66Shc in reprogramming cell metabolism toward glucose catabolism and oxidative respiration.
p66Shc regulates redox homeostasis
By associating with cytochrome c, p66Shc promotes the generation of reactive oxygen species (ROS) (10, 21) . Consistent with these findings, we observed a higher ratio of reduced to oxidized glutathione (GSH/GSSG) in p66Shc KO MEFs compared to p66 + MEFs (Fig. 3D ). The ratio of NADH/NAD + also reflects the redox state of the cell (22), and a nearly threefold increase in NADH/NAD + indicates a more reducing environment in p66Shc-deficient cells (Fig. 3E) . NADH is produced in the second half of glycolysis during the glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-catalyzed step, and this may contribute to the altered NADH/NAD + ratio. The higher GSH/GSSG ratio in KO MEFs is consistent with the reported lower amounts of ROS in p66Shc KO MEFs (21) . A previous report has shown that ROS contributes to insulin resistance and decreases glucose metabolism (23) .
p66Shc is necessary and sufficient to alter glucose uptake and metabolism
To directly test whether p66Shc alters glucose uptake, we measured 3 Hlabeled 2-deoxyglucose (2-DG) uptake at different time points. The rate of 2-DG uptake in p66Shc-deficient HeLa cells and p66Shc KO MEFs was greater than that in p66Shc-expressing cells (Fig. 4 , A and B). Consistent with the enhanced glucose consumption and higher glycolytic metabolism in p66Shc-deficient cells, we observed increased concentrations of extracellular lactate in the media of HeLa cells and MEFs lacking p66Shc (Fig. 4, C and D) . However, Western blots showed no apparent difference in the abundance of glucose transporter 1 (GLUT1) between p66Shc-competent and p66Shc-deficient cells ( fig. S3) .
To monitor the effect of p66Shc on glucose catabolism, we examined the metabolites of 13 C-labeled glucose in control and p66Shc-deficient HeLa cells. The metabolism of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose generates M0, M1, and M2 mass isotopomers corresponding to ion fragments that contain zero, one, or two labeled carbons, respectively (table S2). The rapid transfer of cells from unlabeled medium to identical medium containing [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose ensures that metabolism is minimally disturbed (24) . Consistent with enhanced glycolytic metabolism in p66Shc-depleted cells, the amounts of the M2-labeled form of G6P and downstream intermediates including M2 F6P and M2 pyruvate were increased in p66Shc-depleted HeLa cells (Fig. 4 , F and G). p66Shc silencing enhanced the amount of labeled glucose-derived citrate and acetyl-CoA nearly twofold, consistent with the redirection of glucose-derived carbons toward lipid biosynthesis. Conversely, reexpressing p66Shc in p66Shc KO MEFs inhibited the increase in the abundance of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]-labeled glycolytic metabolites and downstream anabolic intermediates, including acetyl-CoA and citrate, in p66Shc-deficient cells (Fig. 4H) . Additionally, p66Shc inhibited the de novo synthesis of amino acids ( fig. S4) . Collectively, our data suggest that p66Shc is necessary and sufficient to reprogram glucose utilization into anabolic pathways.
Lack of p66Shc enhances glycolytic flux and anabolic metabolism
To study the dynamics of incorporation of isotope-labeled glucose into downstream anabolic metabolites, we performed kinetics flux profiling in p66Shc KO and p66 + MEFs, using [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose, by measuring the relative amounts of labeled glycolytic intermediates over six time points (0, 1, 2.5, 5, 10, and 15 min). Consistent with the steady-state data, we found that p66Shc inhibited labeled glucose flux into glycolytic intermediates such as pyruvate in p66 + MEFs (Fig. 5A ). In addition, the amounts of labeled citrate, UDP-GlcNAc, and R5P were lower in cells expressing p66Shc In all experiments, error bars represent SD of at least three biological replicates (*P < 0.05, ***P < 0.001).
( Fig. 5 , B to D). UDP-GlcNAc is a highenergy donor required for protein glycosylation and an example of an anabolic metabolite in which the GlcNAc portion is not catabolized back to glucose (20) . Overall, these results suggest that increased glycolytic flux in p66Shc-deficient cells accounts for the observed increase in metabolites at steady state, consistent with a role for p66Shc as an inhibitor of glucose catabolism.
p66Shc inhibits growth factor signaling to the metabolic sensor mTOR
Several aspects of the metabolic profile of p66Shc KO MEFs resemble those of cells with chronic mTOR activation; these include enhanced amounts of glycolytic and pentose phosphate pathway intermediates (G6P, F6P, and R5P) (25) , increased amounts of de novo pyrimidine metabolites (26, 27) , and increased lipid biosynthesis precursors (acetylCoA and malonyl-CoA) (25) . To monitor mTOR signaling, we examined phosphorylation of Thr 389 in the ribosomal protein S6 kinase (S6K1), a substrate of mTORC1, and of Thr 473 in Akt, which is a direct target of mTORC2 (28) . After serum stimulation, p66Shc-deficient HeLa cells displayed markedly increased phosphorylation of both mTORC1 and mTORC2 targets compared to control cells, despite having equal abundance of the p52Shc and p46Shc isoforms (Fig. 6A) . Similar results were obtained with insulin stimulation (Fig. 6B) . Pretreatment of cells with the mTOR inhibitor Torin1 (29) abolished the phosphorylation of mTOR targets in both cell types, confirming the specificity of the signal (Fig. 6,  A and B) . We also found that amino acid activation of the mTORC1 pathway was enhanced in p66Shc-deficient HeLa cells ( fig. S5A ). In p66 + MEFs, p66Shc inhibited the activation of mTOR targets after stimulation with insulin-like growth factor 1 (IGF-1) and insulin, but not with epidermal growth factor (EGF) (Fig. 6C) . This observation is consistent with previous reports showing that p66Shc has little effect on EGF signaling (9) . The phosphorylation of mTORC1 and mTORC2 targets was decreased in p66 + MEFs after serum (Fig. 6D) and amino acid stimulation (fig. S5B) . In contrast to the inhibitory effects of p66Shc expression on mTOR signaling in KO MEFs, mTOR activation was sustained in KO MEFs stably overexpressing the p52Shc isoform (Fig. 6E) . This confirms earlier reports that the p66Shc and p52Shc isoforms have opposing effects attributable to the unique N-terminal CH2 region of p66Shc (9, 30).
Loss of p66Shc causes an increase in cell size
mTOR functions as a central regulator of cell growth (31) . The inhibitory effect of p66Shc on mTOR activation therefore predicted that p66Shc deficiency would lead to a larger cell size. Indeed, stable reexpression of p66Shc in p66Shc KO MEFs caused a decrease in cell size as measured by FACS (fluorescence-activated cell sorting) forward scatter analysis (Fig. 6F) . These findings were confirmed using Coulter counter measurement ( fig.  S6A ). Conversely, HeLa cells depleted of p66Shc displayed an increase in median cell size, consistent with redirection of glucose-derived carbon toward biomass synthesis ( fig. S6B ). Together, these results suggest that p66Shc acts as a negative regulator of the nutrient-sensing mTOR signaling pathway, leading to inhibition of cell growth and anabolic metabolism.
The effects of p66Shc on glycolytic metabolism are mediated through mTOR
To determine which mTOR complex contributes to the metabolic phenotype observed in p66Shc null cells, we treated p66Shc KO and p66 + MEFs with rapamycin for 16 hours, a time frame that inhibits both mTORC1 and mTORC2 enzymes (Fig. 7A ). In line with reports linking mTORC1 and mTORC2 to glycolytic metabolism (25, 32, 33) , we found that inhibition of both mTOR complexes partly reversed the metabolic phenotype of p66Shc KO MEFs, notably diminishing the increase in the hexosamine biosynthesis pathway (UDP-GlcNAc) and the pentose phosphate pathway (R5P) (Fig. 7B) . A similar trend was observed in de novo pyrimidine synthesis (Fig. 7C) . Furthermore, inhibition of Akt, a kinase that is upstream of mTORC1 and downstream of mTORC2 (28), significantly decreased the amounts of glycolytic metabolites in p66Shc-deficient MEFs ( fig. S7 ).
p66Shc alters gene expression
To understand how p66Shc signals to mTORC1 and mTORC2, we attempted to find unique p66Shc binding partners by MS. However, all proteins that bound to p66Shc in our experiments have also been reported to bind to p52Shc after serum stimulation (table S4) (34) . The steady-state condition of p66Shc KO and p66 + MEFs is likely to include differences in gene expression. To address this question, we performed RNA sequencing (RNA-seq) analysis comparing the expression profiles of p66Shc KO and p66 + MEFs. Our data showed significant differences in the expression of about 400 genes but not for genes encoding glycolytic enzymes, including hexokinase and phosphofructokinase, or those encoding glucose transporters (table S3) . This suggests that changes in steady-state abundance of p66Shc regulate metabolism largely through signaling and posttranslational modification. independent experiments is represented (left). ***P < 0.001.
DISCUSSION
Our results provide evidence that p66Shc expression is associated with dampened signaling response to insulin stimulation and reduced glycolytic metabolism. Hyperglycemia has been previously shown to induce p66Shc expression (35) . Our data suggest that p66Shc mediates feedback inhibition of growth signaling and glucose metabolism in cells (Fig. 7D) . For metabolites that are intermediates in both catabolic and anabolic directions, the delivery of 13 C-labeled glucose reveals competing delivery from cold sources including storage products, autophagy, and uptake of other nutrients. For central metabolites such as pyruvate, citrate, R5P, and UDP-GlcNAc, our flux analysis showed faster 13 C incorporation and an increase to a higher steady state in p66Shc-deficient cells, indicating a larger contribution from 13 C-glucose than the nonradioactive sources in cells lacking p66Shc.
Furthermore, p66Shc deficiency in mice improves glucose tolerance and insulin sensitivity (13, 14) . p66Shc silencing in both transformed and nontransformed immortalized cells improves glucose uptake and increases lactate production, metabolite abundance for fatty acid biosynthesis, the hexosamine pathway, and the pentose phosphate pathway, and amino acids, contributing to increased cell size. This metabolic shift depends in part on the mTOR pathway because rapamycin treatment reversed the glycolytic shift caused by p66Shc loss (Fig. 4D) . These effects are particularly striking because the p52Shc isoform is identical to p66Shc in all but the N-terminal CH2 region, and has the opposing function of promoting the activation of the Ras-ERK and PI3K-Akt pathways. p66Shc acts as an inhibitor of mTORC1 and mTORC2 signaling, pathways that support protein synthesis associated with increased cell size. mTOR inhibition reduced anabolic metabolites, partially restoring the p66Shc-competent phenotype, suggesting that mTOR-independent pathways also contribute to the p66Shc-deficient phenotype. p66Shc expression has been reported to be inversely correlated to tumorigenesis (12) , which is consistent with our finding that p66Shc loss enhances mTOR signaling and anabolic metabolism. It is possible that p66Shc competes with p52Shc for binding partners in a dynamic manner that disrupts downstream signaling to mTOR. Time courses for receptor recruitment of signaling complexes may reveal the molecular basis for p66Shc action on signaling and anabolic metabolism. RNA-seq analysis showed no differences in the expression of genes encoding metabolic enzymes and glucose transporters between p66Shc-competent and p66Shc-deficient cells. Transcripts showing a change in abundance were clustered in the category of secretory proteins, and additional studies are required to assess their contribution to the p66Shc phenotype. Rapid forms of regulation such as allostery and posttranslational modifications to metabolic enzymes and transporters may account for much of the observed p66Shc-dependent metabolic reprogramming. However, on a longer time scale, the stable cell lines used in our experiments have adapted to p66Shc expression or loss, and the attendant changes in signaling and metabolism flux may be reinforced by some of the changes in gene expression.
In summary, our results indicate that the Shc1 locus not only regulates mitogenic signaling but also modifies anabolic metabolism in an mTOR-dependent manner. Our data point to the prospect that monitoring or modulating p66Shc abundance could be important in the management of pathological conditions in which metabolic signaling is dysregulated, such as cancer and diabetes.
MATERIALS AND METHODS
Reagents were obtained from the following sources: antibodies to phospho-Thr 389 S6K1, phosho-Thr 308 Akt, phospho-Ser 473 Akt, Akt, and S6K1 from Cell Signaling Technology; mouse and rabbit Shc1 antibodies from BD Transduction Laboratories; FLAG and tubulin antibodies, amino acids, insulin, IGF-1, and EGF from Sigma-Aldrich; FuGENE 6 and Complete Protease Cocktail from Roche; rapamycin from LC Laboratories; Dulbecco's modified Eagle's medium (DMEM) from Gibco; inactivated fetal calf serum (IFS) from HyClone; amino acid-free RPMI from US Biological; bicinchoninic acid assay reagent and protein G-Sepharose from Pierce; and Akt Inhibitor IV from EMD4Biosciences.
Cell lines and tissue culture
HeLa cells and MEFs were cultured in DMEM with 10% IFS and penicillin/ streptomycin. p66Shc KO MEFs were provided by P. G. Pelicci (IFOM). 3xFLAG-p66Shc-expressing MEFs were generated by retroviral infection of gateway-compatible pMX vector with murine p66Shc complementary DNA (cDNA). Stably infected cells were maintained under puromycin (1 µg/ml) selection. For stable p66Shc knockdown in HeLa cells, we used the following hairpin sequence: sense, 5′-cggaatgagtctctgtcatcgct(tt)-3′; antisense, 5′-agcgatgacagagactcattccg(tt)-3′.
Amino acid stimulation
Almost confluent cultures in six-well culture plates were rinsed once with amino acid-free RPMI, incubated in amino acid-free RPMI for 50 min, and stimulated with leucine (52 mg/ml) for 10 min. For amino acid starvation, cells in 10-cm culture dishes or coated glass coverslips were rinsed with and incubated in amino acid-free RPMI for 50 min and stimulated with a 10× amino acid mixture for 10 min as indicated in the figure legends. After stimulation, the final concentration of amino acids in the media was the same as that in RPMI. The 10× amino acid mixture was prepared from individual amino acid powders.
Cell lysis and Western blots
Cells were rinsed once with ice-cold phosphate-buffered saline (PBS) and lysed in ice-cold lysis buffer [40 mM Hepes (pH 7.4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 0.5% NP-40, and one tablet of EDTA-free protease inhibitors (Roche) per 10 ml]. The soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 min by centrifugation in a microfuge.
Proteins were denatured by the addition of 2× sample buffer and boiling for 5 min, resolved by 8% SDS-polyacrylamide gel electrophoresis, and analyzed by immunoblotting for the indicated proteins in the figures.
Metabolomic profiling
The relative abundances of metabolites were determined in HeLa cells and MEFs using the following protocol (36): Cells were seeded in six-well plates in replicates. After 24 hours, the media were removed; the cells were washed two times with warm PBS and were placed on dry ice. The metabolites were immediately extracted by adding 1 ml of extraction solution (40% acetonitrile, 40% methanol, and 20% water) containing internal standards [D7-glucose and 13C915N-tyrosine (500 and 300 µg/ml, respectively)], and then the cells were scraped and collected in 1.5-ml vials. The mixture was shaken for 1 hour at 4°C and 1400 rpm in a Thermomixer (Eppendorf). The samples were spun down at 14,000 rpm for 10 min at 4°C (Eppendorf), and supernatants were transferred into fresh tubes and evaporated to dryness in a CentreVap concentrator at 40°C (Labconco). The dry extract samples were stored at −80°C until LC/MS analysis. The dry metabolite extracts were reconstituted in 100 µl of water. For positive-and negative-mode analysis, the sample was injected twice through a reversedphase column (Inertsil ODS-3, 4.6-mm internal diameter, 150-mm length, and 3-µm particle size; Dionex Corporation). In positive-mode analysis, the mobilephase gradient ramped from 5 to 90% of acetonitrile in 16 min; after 1 min at 90%, the composition returned to 5% acetonitrile in 0.1% acetic acid in 2 min. In negative mode, the acetonitrile composition ramped from 5 to 90% in 10 min; after 1 min at 90%, the gradient returned to 5% acetonitrile in buffer A (0.1% tributylamine, 0.03% acetic acid, 15% methanol). The total run time in both modes was 20 min, the samples were stored at 4°C, and the injection volume was 10 µl. An automated washing procedure was developed before and after each sample to avoid any sample carryover.
The eluted metabolites were analyzed at the optimum polarity in MRM mode on an electrospray ionization triple-quadrupole mass spectrometer (ABSciex4000Qtrap). The MS data acquisition time for each run was 20 min, and the dwell time for each MRM channel was 10 ms. Common MS parameters were the same as the tuning conditions described above, except GS1 and GS2 were 50 psi; CUR was 20 psi; CAD was 3 and 7 for positive and negative modes, respectively; and source temperature (TEM) was 400°C. Signal was normalized to internal standard and cell number. MetaboAnalyst was used to analyze the data (37) . The LC-MS/MS system does not resolve hexose and hexosamine isomers including glucose/galactose and GlcNAc/GalNAc (N-acetylgalactosamine). To monitor trends in metabolic pathways, we referred to these isomers in their glucose (Glc) forms.
Statistics
Unpaired two-tailed Student's t tests were performed for comparing two groups. For multiple comparison analysis, one-way ANOVA followed by Bonferroni's post hoc test was used. All experiments represent at least three biological replicates. H-labeled 2-DG (0.2 mCi/ml) at room temperature. The reaction was terminated by washing three times in ice-cold 0.9% NaCl (w/v). To quantify the radioactivity incorporated, cells were lysed with 0.05 N NaOH, and lysates were counted with scintillation fluid in a b-counter. Nonspecific uptake was determined in the presence of cytochalasin B (10 mM) during the assay. The results are expressed as picomoles of 2-DG transported per milligram of protein per minute.
Oxygen consumption rate measurement
Cells were seeded at 50,000 cells per well in XF-24 cell culture plates. The day after the seeding, cell culture medium was replaced with unbuffered RPMI, and oxygen consumption was measured using an XF-24 flux analyzer as described in (38) .
Isotope labeling and kinetic profiling
Media of cell cultures in six-well dishes were replaced with unlabeled fresh DMEM 2 hours before exposure to labeled glucose. The media were then replaced with DMEM containing 25 mM [1,2- 
MS analysis of the p66Shc protein interactions
The p66Shc protein interaction network was determined following a protocol described in (34) . p66 + MEFs were washed three times with ice-cold PBS and lysed in NP-40 lysis buffer [50 mM Hepes-NaOH (pH 8), 150 mM NaCl, 1 mM EGTA, 0.5% NP-40, 100 mM NaF, 2.5 mM MgCl 2 , 10 mM Na 4 P 2 O 7 , 1 mM dithiothreitol, 10% glycerol] supplemented with protease and phosphatase inhibitors [50 mM b-glycerophosphate, aprotinin (10 µg/ml), leupeptin (10 µg/ml), 1 mM Na 3 VO 4 , 100 nM calyculin A, 1 mM phenylmethylsulfonyl fluoride]. The total cell lysates were centrifuged at 10,000 rpm for 15 min to pellet nuclei and insoluble material. Nuclear-free lysates were precleared by 1-hour incubation with protein A-Sepharose and normalized for total protein concentration using the Bio-Rad protein assay. 3xFLAG-p66Shc was immunoprecipitated by incubating lysates with 5 µl (bed volume) of anti-FLAG M2 antibody-conjugated agarose for 4 hours at 4°C.
RNA sequencing
cDNA library preparation was done using the Illumina TruSeq RNA Sample Prep Kit v2 (cat. no. RS-122-2001). Briefly, 1 µg of high-quality total RNA was isolated from p66Shc KO and p66 + MEFs to generate the cDNA library according to the manufacturer's protocol. The generated bar-coded cDNA library had an average fragment size of 350 to 400 base pairs. This bar-coded library was quality-checked with the Agilent Bioanalyzer and quantified by quantitative polymerase chain reaction (qPCR) with KAPA SYBR FAST Universal 2x qPCR Master Mix (Kapa Biosystems, cat. no. KK4602). The quality-checked libraries were then loaded on a flow cell for cluster generation using Illumina cBot and TruSeq PE Cluster Kit v3 (cat. no. PE-401-3001). Sequencing was done on HiSeq2000 with TruSeq SBS Kit v3 (paired-end, 200 cycles, cat. no. FC401-3001). The real-time base call (.bcl) files were converted to FASTQ files using CASAVA 1.8.2 (on CentOS 6.0 data storage and computation Linux servers).
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